Immutep (IMMP) said Thursday its investigational drug eftilagimod alpha, or efti, combined with Merck's (MRK) Keytruda and doublet chemotherapy achieved a response rate of 60.8% and disease control rate of 90.2% in patients with advanced or metastatic non-squamous non-small cell lung cancer in an investigator-initiated trial.
The company said the 60.8% response rate regardless of PD-L1 expression is a "substantial improvement" from the historical control of 48%.
Safety continues to be favorable for the triple combination, the company said.
Immutep said it expects to present additional data from the trial at a medical conference within the year.
Shares of Immutep climbed 9.3% in recent premarket activity Thursday, while Merck shares added 1%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.